Method and reagents for the detection of a mammalian antibody
AssigneesEUROIMMUN Medizinische Labordiagnostika AG, Klinisch-immunologisches Labor Prof. h.c. (RCH) Dr. med. Winfried Stöcker
InventorsMadeleine SCHARF, Ramona Miske, Stefan Schöbel, Winfried Stöcker, Christiane Radzimski, Kathrin Borowski, Merle Corty
Life of this patent
Estimating the term…
Abstract
A method includes detecting in a sample a mammalian antibody binding specifically to ZSCAN5. A mammalian antibody binds specifically to ZSCAN5, and a carrier with a solid phase with at least one immobilized polypeptide includes at least one epitope of ZSCAN5 or a variant thereof. The mammalian antibody is used for diagnosing a neurological autoimmune disease or a cancer.
Claims20
A method, comprising:
- detecting in a sample a mammalian antibody binding specifically to ZSCAN5.
A method for isolating a mammalian antibody binding specifically to ZSCAN5, comprising:
- a) immobilizing on a carrier at least one polypeptide comprising at least one epitope of ZSCAN5 or a variant thereof,
- b) contacting a sample comprising antibodies with the at least one polypeptide under conditions compatible with formation of a complex, wherein said antibody binds to said polypeptide,
- c) separating the complex formed in step a) from the sample,
- d) optionally separating the antibody from the polypeptide, and
- e) optionally detecting the antibody or complex.
A method, comprising:
- contacting a polypeptide comprising at least one epitope of ZSCAN5 or a variant thereof with a liquid comprising a mammalian antibody binding specifically to ZSCAN5, wherein a candidate drug is present and/or the liquid does not comprise a sample from a subject to be diagnosed, and
- detecting binding of the antibody.
A mammalian antibody binding specifically to ZSCAN5.
A carrier, comprising:
- a solid phase comprising at least one immobilized polypeptide comprising at least one epitope of ZSCAN5 or a variant thereof and a) a negative and/or positive control and/or b) at least one additional diagnostically useful antigen, wherein the at least one immobilized polypeptide and the negative and/or positive control or additional antigen are spatially separate on the carrier,
- or a first carrier with a solid phase comprising at least one immobilized polypeptide comprising at least one epitope of ZSCAN5 or a variant thereof and a second carrier comprising a solid phase comprising an immobilized a) negative and/or positive control and/or b) at least one additional polypeptide comprising an immobilized antigen or a variant thereof.
Dependencies are inferred from the claim text.